Forsinkede kurser. Sist oppdatert: mandag 22. april  

12/12-2018 16:54:40: (TRVX) Targovax Presents at DNB 9th Annual Nordic Healthcare Conference

Oslo, Norway, 12 December 2018 - Targovax ASA (OSE: TRVX), a clinical stage
biotechnology company developing immune activators to target hard-to-treat solid
tumors, announces that CEO Øystein Soug presented today at DNB 9th Annual Nordic
Healthcare Conference in Oslo, Norway.
The presentation provided a corporate overview, highlighting the Company's two
platform technologies including clinical data from its lead pipeline asset,
ONCOS-102, an oncolytic adenovirus, and the TG cancer vaccine program that
targets tumors that express mutated forms of RAS - mutations known to drive
cancer.

Please see the presentation attached. TRVX DNB presentation
 (https://mb.cision.com/Public/17093/2698730/b5e0270377c81c80.pdf)

The presentation is also available to download at www.targovax.com.
For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media and IR enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no
Simon Conway/Stephanie Cuthbert - FTI Consulting (International)
Phone: +44 20 3727 1000
Email: Targovax@fticonsulting.com
About Targovax

Activating the patient's immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage biotechnology company developing immune
activators to target hard-to-treat solid tumors. Immuno-oncology is currently
one of the fastest growing therapeutic fields in medicine.

Targovax's lead product candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect and
replicate in cancer cells. It has been shown to activate the immune system to
generate tumor-specific immune responses. In phase I trials, ONCOS-102 induced
both local and systemic innate and adaptive immune activation, which has been
associated with clinical benefit. ONCOS-102's lead indication is mesothelioma,
where the virus is currently being tested in a randomized phase II trial, with a
phase Ib safety lead-in cohort. Another trial, in advanced melanoma, is expected
to produce important proof of concept data for checkpoint inhibitor refractory
patients.

Targovax is also developing a neo-antigen cancer vaccine targeting tumors that
express mutated forms of RAS - mutations known to drive cancer. The TG vaccine
program has shown a signal of efficacy compared to historical control in a 32
-patient trial with TG01 in resected pancreatic cancer. A next generation
product candidate, TG02 is currently tested as monotherapy and will also be
tested in combination with KEYTRUDA® (an anti-PD1 check point inhibitor, CPI)

Ekstern link: https://newsweb.oslobors.no/message/465635

Nyheten er levert av OBI.